Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: Voters in both Western states approved ballot initiatives in 2012 allowing personal possession and use of marijuana by anyone aged 21 and or older for purposes of just getting high, though public consumption of pot remains illegal. In January the world’s first state-licensed retail marijuana outlets opened for business in Colorado, and stores in Washington are set to follow suit later this year. Both states are among 20 that have already removed criminal sanctions for medical use of marijuana. The federal government still classifies marijuana as an illegal narcotic, but the Obama administration has given states new leeway to experiment with legalized cannabis. In Denver’s Civic Center Park near the state capitol, revelers on Sunday gathered to hear music and listened to speakers during a weekend event that organizers billed as the “world’s largest 4/20 rally.”  The date of April 20, or 4/20, corresponds to the numerical code widely recognized within the cannabis subculture as a symbol for all things marijuana. Police officers standing by on the fringes of the Denver festival issued 63 citations on Sunday, most for smoking pot in public - a ticket that carries a fine of $150. About half as many were cited on Saturday, police said. At least eight individuals were taken to a detoxification facility for treatment during the two days, police said. Denver police spokesman Sonny Jackson said officers have refrained from wading into the crowd to arrest violators, but instead were citing people who openly defied the public consumption ban. “Those ticketed were blatantly in violation of state law and city ordinances,” Jackson said. Organizers of the rally and city officials beefed up security at the event after three people were wounded by gunfire at last year’s rally. Separately, the Cannabis Cup, a trade show sponsored by High Times magazine, drew sold-out crowds over the weekend at a Denver convention venue. The two-day event featured marijuana sampling and workshops, such as how to open a pot shop, cultivation tips, and how to talk to children about weed, according to the event’s website. Rachel O’Bryan, spokeswoman for Smart Colorado, an organization that advocates for stricter enforcement of marijuana laws, said the cannabis industry needs to do more to police its own. “People are flouting the law by openly consuming,” she said. “We’re concerned about the message that sends to our kids.”  In Seattle, several hundred people who paid $15 a head crowded the cavernous interior of a former brewery where Rainier Beer was made for decades to attend a 4/20 gathering organized by sponsors of the city’s annual Hempfest rally. Reggae music played over loudspeakers and the air inside was thick with the sweet, skunky odor of cannabis. But no police were visible at the event, which organizers deliberately held on private space leased from the brewery owners in an industrial section of the city south of downtown. The gathering featured a workshop on how to roll a joint with an entire ounce (28 grams) of marijuana - the legal limit for personal possession in the state - as well as vendors selling pipes and other paraphernalia, and a blind-toke test in which participants tried to distinguish between different strains of pot by sampling them. Attendees ranged from middle-aged baby boomers to a younger crowd from the so-called millennial generation. A cheer from the crowd went up at precisely 4:20 p.m. local time, as many attendees milling about outside lit joints and pipes simultaneously, sending puffs of smoke into the air followed by raucous fits of coughing. One woman in the crowd accepted a joint handed her from a bearded bystander. “You look just like Jesus,” she exclaimed in an apparent reference to the event coinciding with Easter Sunday. “How does it feel to be risen?”  Doug Medina, 54, said he traveled hundreds of miles with his wife and daughter from Billings, Montana, to Seattle for the 4/20 weekend celebrations there. “It feels a little more open than it did five or 10 years ago,” he said while smoking a joint outside the brewery. Claim: Marijuana fans pack 4/20 events in Colorado, Washington state.

A: Thousands of marijuana enthusiasts gathered in Colorado and Washington state over the weekend for an annual celebration of cannabis culture with rallies, concerts and trade shows in the first two U.S. states to legalize recreational marijuana.
****
Q: Paragraph: The Food and Drug Administration approved Medtronic’s CoreValve system based on U.S. clinical trials in which it was shown to be safe and effective while demonstrating low rates of stroke and valve leakage, the company said. CoreValve, in which the replacement valve is threaded into place through an artery using a catheter, spares patients chest-cracking surgery. The system has been available since 2007 in Europe, where it is not uncommon for medical devices to win approval several years ahead of the United States. Claim: U.S. FDA approves Medtronic heart valve replacement system.

A: Medtronic Inc’s non-invasive systems for replacing diseased heart valves won U.S. approval for use in patients deemed too frail to endure traditional open heart surgery, the U.S. medical device maker said on Friday.
****
Q: Paragraph: J&J’s view on naming of biosimilars contrasts that of Mylan Inc and Novartis AG over the past few months, as the U.S. Food and Drug Administration continues to work on drafting regulations for the approval of biosimilars — cheaper versions of expensive biologics, or the original reference drugs. “Assigning names that are similar but not the same will appropriately reflect the legal and scientific reality that biosimilars are similar to but not the same as their reference products or other biosimilars,” J&J’s Chief Biotechnology Officer Jay Siegel said in a statement. Creating copies of biologics is complicated as these products are produced in living cells, bringing inevitable unpredictability. As a result, their copies can only ever be “similar,” not exact replicas. Names of biosimilars are also bound to impact their sales and adoption as substitutes to the original products. Novartis and Mylan have both previously expressed support for a system that requires that a biosimilar share the same international non-proprietary name (INN) as the biologic products to which it refers, saying that same names would avoid frivolous brand tactics and confusion in the marketplace. Mylan in September said it supported a petition filed by the Washington, DC-based Generic Pharmaceutical Association that recommended biosimilars have the same names because by definition they are highly similar to their reference products and have no meaningful differences that require a unique name. Novartis advocated for the same by filing its own petition in October. Biologic medicines, typically administered via an injection, and are used to treat cancers, immunological diseases like rheumatoid arthritis and multiple sclerosis and other chronic illnesses, but their high price tag can keep them out of reach for many patients. The FDA in February 2012 issued draft guidance on approval pathways for biosimilars, but is yet to finalize that guidance, while European regulators have already cleared cheaper copies of some biotech medicines. The global biosimilars market is expected to be worth about $11 billion to $25 billion in 2020, equivalent to a modest 4 to 10 percent of total biotech drug sales by that time, according to healthcare information firm IMS Health. Claim: J&J petitions FDA to require 'similar' names for biosimilars, biologics.

A:
Johnson & Johnson on Wednesday said it submitted a citizen petition asking that U.S. health regulators require copies of biological products to bear names that are similar and not identical to those of their reference products.
****